Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 16
2003 19
2004 25
2005 39
2006 31
2007 45
2008 47
2009 70
2010 61
2011 64
2012 96
2013 103
2014 104
2015 105
2016 113
2017 116
2018 155
2019 168
2020 204
2021 244
2022 288
2023 291
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

2,211 results

Results by year

Filters applied: . Clear all
Page 1
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Among authors: zhou h. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y. Lu S, et al. Among authors: zhou h. Lancet Respir Med. 2023 Jul;11(7):624-636. doi: 10.1016/S2213-2600(23)00135-2. Epub 2023 May 5. Lancet Respir Med. 2023. PMID: 37156249 Clinical Trial.
1-Deoxynojirimycin promotes cardiac function and rescues mitochondrial cristae in mitochondrial hypertrophic cardiomyopathy.
Zhuang Q, Guo F, Fu L, Dong Y, Xie S, Ding X, Hu S, Zhou XD, Jiang Y, Zhou H, Qiu Y, Lei Z, Li M, Cai H, Fan M, Sang L, Fu Y, Zhang D, Lin A, Li X, Kunath T, Zhou R, Liang P, Liu Z, Yan Q. Zhuang Q, et al. Among authors: zhou h. J Clin Invest. 2023 Jul 17;133(14):e164660. doi: 10.1172/JCI164660. J Clin Invest. 2023. PMID: 37200096 Free PMC article.
Stimuli-Responsive Nanotechnology for RNA Delivery.
Zhou H, Chen DS, Hu CJ, Hong X, Shi J, Xiao Y. Zhou H, et al. Adv Sci (Weinh). 2023 Dec;10(36):e2303597. doi: 10.1002/advs.202303597. Epub 2023 Nov 1. Adv Sci (Weinh). 2023. PMID: 37915127 Free PMC article. Review.
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, Guo J, Su W, Fan S, Tan P, Wang Y, Luo Y, Zhou H, Li J. Guo Y, et al. Among authors: zhou h. Eur J Cancer. 2023 Mar;181:26-37. doi: 10.1016/j.ejca.2022.12.004. Epub 2022 Dec 13. Eur J Cancer. 2023. PMID: 36628898 Free article. Clinical Trial.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: zhou h. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
2,211 results